Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00152009
Status:
COMPLETED
Last Update Posted:
2021-06-10
First Post:
2005-09-07
Brief Title:
Safety and Efficacy of SPD503 in Treating Attention-DeficitHyperactivity Disorder ADHD in Children Aged 6-17
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Phase III Randomized Multi-Center Double-Blind Parallel-Group Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-DeficitHyperactivity Disorder ADHD
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and efficacy of SPD503 Guanfacine hydrochloride compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None